SCRS Talks

In this episode of SCRS Talks, Lauren Stockwell sits down with Dave Damrau, VP of Global Clinical Operations for the Americas, and Amy Cramer, Global Head of eSource Data Acquisition, both from Johnson & Johnson Innovative Medicine, to unpack J&J's EHR to Sponsor initiative. They discuss why duplicative data entry remains one of the biggest burdens on site staff, what the data shows about the time and error costs of manual transcription, and how eSource solutions are already improving data accuracy. Dave and Amy walk through why oncology became the starting point for this work, what site-driven collaboration has meant for adoption, and what's next as J&J expands EHR to Sponsor into additional therapeutic areas in 2027. Tune in to hear how this initiative aims to reduce friction for sites while creating a more efficient, connected model for clinical research.
Join Dave and Amy for the J&J SCRS Summit EHR Action Panel on October 18th from 9:00 to 10:00 AM.

What happens to unused medical supplies when a clinical trial ends? For years the answer was simple: destroy them. Josh Kravitz (MedSurplus Alliance) and Greg Folz (Kits4Life) join Jimmy Bechtel to tell the story of how a stack of boxes, a looming Site Tank deadline, and a crisis in the Congo turned into a program that has now impacted over 6 million lives worldwide. Greg walks through the moment his research staff refused to keep destroying usable supplies, and how that frustration became an idea that won on stage and grew into an industry wide movement. Josh breaks down how trusted partnerships and strict chain of custody get donated supplies from a research site to a clinic or classroom halfway around the world. It's a conversation about waste, generosity, and what's possible when sites push their sponsors to think differently about what happens after a trial ends.

Jimmy Bechtel sits down with Dr. Tia Warrick, CEO of Lesous Consulting, to talk about what actually drives clinical trial failures and what the industry can do about it. With nearly a decade of experience spanning coordinator to CEO, Dr. Warrick brings a ground-level perspective to a problem that costs the industry billions.
The conversation covers why so many trials struggle before enrollment even begins, the difference between foundational certifications and true skills-based competency, and what it means that roughly a third of clinical trial failures trace back to workforce gaps we actually have the power to fix. Dr. Warrick also shares her take on where AI fits in, and why it is a useful tool but not a replacement for people who truly know their roles.
If your team is thinking about how to build a more resilient, capable workforce and set trials up for success from day one, this episode is worth your time.

In this episode, Jimmy sits down with Brian Burkhardt of the Oliver Patch Project and Andy Shepherd of Project Outrun to talk about the Patchwork Collective, a growing coalition of pediatric oncology advocacy organizations working to bridge the gap between families battling childhood cancer and the clinical trial world. From a "Pharma at the Table" activation at SCOPE to the upcoming Patches & Pairs launch at Give Kids The World, Brian and Andy share how relationship-building and education are the keys to advancing pediatric representation in clinical research.

Jimmy Bechtel sits down with Kimberly Staeck, Head of Global Site Partnerships and Trial Enablement Solutions at Syneos Health, to dig into what it really means to treat sites as partners rather than execution engines.
Kimberly brings two decades of operational and partnership experience to a conversation that gets honest about where the industry falls short. They cover why sites have learned to tell the difference between being heard and actually listened to, what closing the feedback loop looks like in practice, and why early site involvement in protocol development is a risk mitigation strategy, not a delay. Kimberly also makes a case for shifting away from activity-based metrics and toward shared outcomes that reflect the real health of a partnership.
The throughline is simple: when sites feel valued and supported, patients get better care, staff stay in the field longer, and trials perform. If your organization is serious about moving from transactional to transformational site relationships, this one is worth your time.